Jazz Pharmaceuticals plc Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months
Jazz Pharmaceuticals plc (JAZZ) had Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months of $69.50 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths · last filed 2026-02-24
- 2025-12-31: Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months $69.50M.
- 2024-12-31: Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months $46.30M.
- 2023-12-31: Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months $56.60M.
- 2022-12-31: Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months $51.60M.
| Period end | Unrecorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months |
|---|---|
| 2025-12-31 | $69.50M 10-K · filed 2026-02-24 |
| 2024-12-31 | $46.30M 10-K · filed 2025-02-26 |
| 2023-12-31 | $56.60M 10-K · filed 2024-02-28 |
| 2022-12-31 | $51.60M 10-K · filed 2023-03-01 |
| 2021-12-31 | $73.20M 10-K · filed 2022-03-01 |
| 2021-03-31 | $88.80M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $112.00M 10-K · filed 2021-02-23 |
| 2020-09-30 | $75.40M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $71.70M 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |